87 Total results for product and free and sample content found
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, Scrip: 世界の医...
Download your article pack now for a glimpse of some of the topics that will be covered by our panel of experts during the “Is Biopharma Fit for the New Decade?” webinar.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
Go behind the headlines from Big Pharma’s year-end conferences for insights into the most significant recent M&A and divestment activities. Scrip takes you inside the strategies of pharma’s leading companies as they enter a new decade.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
Go inside the 2020 J.P. Morgan Healthcare Conference with exclusive reporting from Scrip. Explore the most important news from each day, and access exclusive, real-time interviews with pharma and biotech movers and shakers, and discover insights into the trends revealed at this year’s event.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
For Scrip’s annual preview, our journalists asked over 80 industry executives and experts for their predictions of the major trends for 2020. From AI to M&A, gene therapy to the upcoming US election, here’s what to watch for as we begin this new decade.
Topic biosimilars biopharmaceutical
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Meddevicetr...
The 38th Annual J.P. Morgan Healthcare Conference has concluded, and Biomedtracker and Meddevicetracker were there to bring you the important outcomes from the largest and most informative annual healthcare investment symposium in the industry.
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor...
Access vital post-ASH meeting reporting from the expert analysts at Datamonitor Healthcare and Biomedtracker.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Tap Outlook 2020’s essential coverage of medtech, R&D, clinical trials and regulation, manufacturing, and more with your extract from our most powerful report.
Pink Sheet: 世界の薬事規制と承認審査に関するニュース
Novartis finds itself facing possible criminal or civil action for admitted data manipulation on its application for Zolgensma, a gene therapy used to treat children with spinal muscular atrophy (SMA) – manipulation disclosed only after FDA approval. Pink Sheet was the first to report on the drug’s loss of EU accelerated assessment, nearly 3 weeks before the pharma giant admitted to submitting falsified data to FDA. Follow the scandal and anticipate its implications on the industry with Pink Sheet’s coverage and timeline.
Topic cell-and-gene-therapy fda
No Records Found
製品説明＆デモお申込
専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。
＊一部のサービスでは無料トライアルをご利用になれません。
お問い合わせ先
ご質問等ございましたらお気軽にご連絡下さい。
日本（平日：9時～18時）
電話：+81 (0)3 6273 4260
Email：inquiry.jp@informa.com
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。
